Table 2

Baseline clinical and immunological status of Children on ART at Felege Hiwot referral hospital, January 1st, 2006 - March 31st, 2011
Variable Frequency Percent (%)
ART eligibility criteria
  WHO clinical stage 9 1.6
  Immunological/CD4Count 35 6.4
  Both clinical and immunologic 505 92.0
Type of drug at initiation of therapy
  4a(d4T-3TC-NVP) 208 37.9
  4b(d4T-3TC-EFV) 37 6.7
  4c(AZT-3TC-NVP) 258 47.0
  4d(AZT-3TC-EFV) 43 7.8
  Kaletra based 3 0.6
Regimen change during follow up
  Yes 68 12.5
  No 475 87.5
Absolute CD4 count
  CD4 count below the threshold 289 52.6
  CD4 count above the threshold 260 47.4
Developmental History
  Appropriate 531 96.7
  Delayed 9 1.6
  Regressing 9 1.6
Cotrimoxazole preventive therapy
  Yes 287 52.3
  No 262 47.7
Nutritional status
  Underweight 453 82.5
  Normal 92 16.8
  Overweight 4 0.7
WHO clinical staging
  I 45 8.2
  II 128 23.3
  III 317 57.7
  IV 59 10.7
Haemoglobin(520)
  <10gm/dl 103 19.8
  ≥10gm/dl 417 80.2
3rdmonth ART drug adherence (497)
  Good 491 98.8
  Fair 3 0.6
  Poor 3 0.6
OIs during follow up
  Yes 165 30.1
  No 384 69.9
Side effect during follow up(526)
  Yes 49 8.9
  No 477 86.9

Koye et al.

Koye et al. BMC Pediatrics 2012 12:161   doi:10.1186/1471-2431-12-161

Open Data